Executive Summary
Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The Company with a global footprint in 49 countries, world-class manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the world’s emerging and developed markets.
Ranbaxy Laboratories Ltd. officially ceased to exist as a company in 2014, when Sun Pharma acquired it.
History of Ranbaxy
Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. The name Ranbaxy is a portmanteau of the names of its first owners Ranbir and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranbir and Gurbax. After Bhai Mohan Singh’s son Parvinder Singh joined the company in 1967, the company saw an increase in scale.
In the late 1990s, Ranbaxy formed a US company, Ranbaxy Pharmaceuticals Inc., and to support its entry into the pharmaceutical market in United States.
In June 2008, Daiichi-Sankyo acquired a 34.8% stake in Ranbaxy from the family of CEO and Managing Director Malvinder Mohan Singh for USD 2.4 billion.
In November 2008, Daiichi-Sankyo completed the takeover of the company from the founding Singh family in a deal worth $4.6 billion by acquiring a 63.92% stake in Ranbaxy. Ranbaxy’s Malvinder Singh remained as CEO after the transaction. The addition of Ranbaxy Laboratories extended Daiichi-Sankyo’s operations, with the combined company worth about US$30 billion.
In 2009 it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the India operations of Ranbaxy Laboratories.
In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. In the 2012, 2013 and 2014 Brand Trust Reports, Ranbaxy was ranked 161st, 225th and 184th respectively among India’s most trusted brands.
On 7 April 2014 India based Sun Pharmaceutical and Japan based Daiichi Sankyo jointly announced the sale of the entire 63.4% share from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy, were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. After this acquisition, the partner Daiichi-Sankyo was to hold a stake of 9% in Sun Pharmaceutical.
Subsidiaries of Ranbaxy Labs:
As Sun Pharma has effectively acquired Ranbaxy Labs, its subsidiary companies are:
- Aditya Acquisition Company Ltd
- Alkaloida Chemical Company Zrt
- Alkaloida Sweden AB
- AO Ranbaxy
- Basics GmbH
- Be-Tabs Investments proprietary Ltd
- Faststone Mercantile Company Private Limited
- Green Eco Development Centre Limited
- Laboratories Ranbaxy S.L
- Neetnav Real Estate Private Limited
- Office Pharmaceutique Industries et Hospitalier SARL
- OOO Sun Pharmaceutical Industries Ltd
- Open Joint Stock Company BIOSINTEZ
- Ranbaxy (Poland) Sp. Z o.O.
- Ranbaxy (S.A.) (Proprietary) Ltd.
- Ranbaxy (Thailand) Company Limited
- Ranbaxy (U.K.) Limited
- Ranbaxy Europe Limited
- Ranbaxy Farmaceutica Ltda.
- Ranbaxy Gmbh
- Ranbaxy Holdings (U.K.) Limited
- Ranbaxy Ireland Limited
- Ranbaxy Italia S.P.A
- Ranbaxy Nigeria Limited
- Ranbaxy Pharma Proprietary Ltd
- Ranbaxy Pharmaceuticals Canada Inc.
- Ranbaxy Pharmaceuticals Ukraine LLC
- Ranbaxy Pharmacie Generiques
- Ranbaxy(Malaysia) Sdn Bhd
- Realstone Multitrade Private Limited
- Rexcel Egypt Company LLC
- Skisen Labs Private Limited
- Softdeal Trading Company Private Limited
- SPIL DE Mexico S.A.de
- Sun Farmaceutica Do Brasil Ltda
- Sun Global Canada Pty Ltd
- Sun Global Development FZE
- Sun Laboratories FZE
- Sun Pharma ANZ Pty Ltd
- Sun Pharma De Mexico S.A.de
- Sun Pharma De Venezuela, C.A
- Sun Pharma East Africa Ltd
- Sun Pharma Global FZE
- Sun Pharma Healthcare FZE
- Sun Pharma Holdings USA Inc and entities
- Sun Pharma Holdings
- Sun Pharma Industries SAC
- Sun Pharma Japan Ltd
- Sun Pharma Laboratories Limited
- Sun Pharma (Netherlands) B.V.
- Sun Pharma Phillipines Inc.
- Sun Pharma SA Pty Ltd
- Sun Pharma Switzerland Ltd.
- Sun Pharmaceutical (Bangaldesh) Ltd
- Sun Pharmaceutical Industries (Australia) Pty Ltd
- Sun Pharmaceutical Industries (Europe) B.V.
- Sun Pharmaceutical Peru SAC
- Sun Pharmaceuticals France
- Sun Pharmaceuticals Germany GmbH
- Sun Pharmaceuticals Italia S.R.L.
- Sun Pharmaceuticals Korea Ltd
- Sun Pharmaceuticals Morocco Sarlau
- Sun Pharmaceuticals UK Limited
- Sunpharma Egypt LLC
- Taro Pharmaceutical Industries Ltd
- Terapia S.A.
Popular Pharmaceutical Products of Ranbaxy
The top products of Ranbaxy, with their therapeutic areas:
| Abiraterone acetate* | Anti-Cancer |
| Acamprosate Calcium | CNS Stimulant |
| Acitretin | Dermatology |
| Adapalene | Retinoid agent |
| Adefovir Dipivoxil | AntiViral |
| Alendronate Sodium | Anti-Osteoporosis |
| Amifostine Trihydrate* | Radioprotective agent |
| Amisulpride | Anti-Psychotic |
| Amorolfine Hydrochloride | Dermatology |
| Amoxicillin Trihydrate | Antiinfective |
| Anastrozole | Anti-Cancer |
| Aripiprazole* | Anti-Psychotic |
| Asenapine Maleate* | Anti-Psychotic |
| Atazanavir Sulfate | AntiViral |
| Atomoxetine HCl* | ADHD Therapy |
| Atorvastatin Calcium Amorphous | Cardiovascular |
| Atorvastatin Calcium Crystalline | Cardiovascular |
| Atosiban Acetate | Oxytocin Antagonist |
| Azacitidine | Anti-Cancer |
| Benazepril Hydrochloride | Cardiovascular |
| Bendamustine* | Anti-Cancer |
| Bicalutamide | Anti-Androgen |
| Bivalirudin* | Anti-Coagulant |
| Bortezomib* | Multiple Myeloma |
| Bosentan Monohydrate | Cardiovascular |
| Budesonide | Anti-Inlammatory Steroid |
| Buprenorphine HCl | Analgesic |
| Bupropion HCl | Anti-Depressant |
| Calcipotriol Anhydrous | Psoriasis |
| Calcitonin (Salmon) | Anti-Osteoporosis |
| Candesartan cilexetil | Cardiovascular |
| Capecitabine | Anti-Cancer |
| Carboplatin | Anti-Cancer |
| Carvedilol | Anti-Hypertensive |
| Cefaclor | Antiinfective |
| Cefdinir | Antiinfective |
| Cefpodoxime proxetil | Antiinfective |
| Cefprozil | Antiinfective |
| Cefuroxime Axetil | Antibiotic |
| Celiprolol Hydrochloride | Cardiovascular |
| Cephalexin | Antiinfective |
| Cilastatin sodium sterile | Antiinfective |
| Cilazapril | Cardiovascular |
| Cinacalcet HCl* | Calcimimetic |
| Ciprofloxacin | Antiinfective |
| Ciprofloxacin Hydrochloride | Antiinfective |
| Cisplatin | Anti-Cancer |
| Citalopram Hydrobromide | CNS |
| Clarithromycin | Antiinfective |
| Clarithromycin Granules 27.5% | Antiinfective |
| Clarithromycin Granules 43.75% | Antiinfective |
| Clomipramine HCl | Anti-Depressant |
| Clonazepam | Anti-Epileptic |
| Clopidogrel Bisulphate | Anti-Thrombotic |
| Clorazepate Dipotassium | Anxiolytic |
| Colesevelam* | Bile acid Sequestrant |
| Dabigatran Etexilate Mesylate* | Anti-Coagulant |
| Decitabine | Myelodysplastic Syndrome |
| Deferasirox* | Iron Chelator |
| Desloratadine | Anti-Histaminic |
| Desmopressin Acetate | Vasopressin Analogue |
| Desvenlafaxine Fumarate | Anti-Depressant |
| Divalproex Sodium | Anti-Epileptic |
| Dobutamin HCl | Cardiovascular |
| Donepezil HCl | Anti-Alzheimer |
| Doripenem | Antiinfective |
| Dothiepin HCl | Anti-Depressant |
| Doxercalciferol* | Hyperparathyroidism |
| Doxycycline | Antiinfective |
| Doxycycline Hyclate | Antiinfective |
| Dronedarone | Anti-Arrhythmic |
| Drospirenone | Oral Contraceptive |
| Duloxetine | Anti-Depressant |
| Dydrogesterone | Hormone Replacement Therapy |
| Edaravone | Neuroprotective |
| Emtricitabine | AntiViral |
| Entecavir | AntiViral |
| Epinastine HCl | Anti-Histaminic |
| Epinephrine | Neurotransmitter |
| Epoprostenol Sodium | Prostaglandin |
| Eptiibatide* | Anti-Thrombotic |
| Escitalopram Oxalate | Anti-Depressant |
| Esomeprazole Magnesium (Amorphous) | Gastrointestinal |
| Esomeprazole Sodium | Proton pump inhibitor |
| Eszopiclone | Hypnotic |
| Exemestane | Anti-Cancer |
| Exenatide * | Anti-Diabetic |
| Febuxostat Form G | Antigout |
| Fesoterodine Fumarate* | Overactive bladder |
| Fexofenadine Hydrochloride | Antihistamine |
| Finasteride | Anti-Testosterone for BPH |
| Fingolimod Hydrochloride* | Immuno modulator |
| Flupirtine Maleate | Analgesic |
| Flurbiprofen | NSAID |
| Fluticasone Propionate | Anti-Allergic |
| Fluvastatin sodium | Cardiovascular |
| Fluvoxamine Maleate | Anti-Depressant |
| Fosamprenavir Calcium | AntiViral |
| Fosinopril sodium | Cardiovascular |
| Fosphenytoin Sodium | Anti-Epileptic |
| Fulvestrant | Anti-Cancer |
| Gabapentin | Anti-Epileptic |
| Galantamine Hydrobromide | CNS |
| Ganirelix Acetate* | GnRH Antagonist |
| Gemcitabine HCl | Anti-Cancer |
| Granisetron HCl | Anti-Emetic |
| Ibandronate Sodium | Anti-Osteoporosis |
| Imatinib Mesylate * | Anti-Cancer |
| Imipenem | Antiinfective |
| Irbesartan | Cardiovascular |
| Irinotecan | Anti-Cancer |
| Isotretinoin | Dermatology |
| Lacosamide* | Anti-Epileptic |
| Lamivudine | AntiViral |
| Lansoprazole | Gastrointestinal |
| Lenalidomide* | Anti-Cancer |
| Lercanidipine HCl | Anti-Hypertensive |
| Letrozole | Anti-Cancer |
| Leuprolide Acetate | Anti-Cancer |
| Levalbuterol HCl | Anti-Asthmatic |
| Levalbuterol Tartrate* | Anti- Asthmatic |
| Levetiracetam | Anti-Epileptic |
| Levocetirizine di HCl | Anti-Histaminic |
| Levofloxacin | Antiinfective |
| Levosulpiride | Anti-Psychotic |
| Linagliptin * | Anti-Diabetic |
| Liothyronine Sodium | Hormone Replacement Therapy |
| Lisinopril | Cardiovascular |
| Lopinavir | AntiViral |
| Loratadine | Antihistaminic |
| Lorazepam | CNS |
| Losartan Potassium | Anti-Hypertensive |
| Loteprednol Etabonate | Corticosteroid |
| Lubiprostone * | Laxative |
| Lurasidone HCl | Schizophrenia |
| Magnesium Valproate | Anti-Epileptic |
| Meloxicam | NSAID |
| Memantine HCl | Anti-Alzheimer |
| Meropenem | Antiinfective |
| Mesalazine/Mesalamine | Anti-Inlammatory |
| Metadoxine | Alcohol Abuse |
| Metformin HCl | Anti-Diabetic |
| Methyl Phenidate HCl | CNS Stimulant |
| Metoprolol Succinate | Anti-Hypertensive |
| Metoprolol Tartrate | Anti-Hypertensive |
| Midazolam | CNS |
| Mifepristone | Abortifacient |
| Milnacipran Hydrochloride | CNS |
| Mirtazapine Hemihydrate | Anti-Depressant |
| Montelukast Sodium | Anti-Asthmatic |
| Naloxone HCl | Opioid Antagonist |
| Naltrexone HCl | Opioid Antagonist |
| Naratriptan HCl | Anti-Migraine |
| Nevirapine | AntiViral |
| Octreotide Acetate | Anti-Cancer |
| Ofloxacin | Antiinfective |
| Olanzapine | Anti-Psychotic |
| Olopatadine HCl * | Anti-Allergic |
| Omeprazole Magnesium | CNS |
| Ondansetron Base | Anti-Emetic |
| Ondansetron HCl | Anti-Emetic |
| Orlistat | Antiobesity |
| Oxaliplatin | Anti-Cancer |
| Oxcarbazepine | Anti-Epileptic |
| Oxetacaine | Local-Anaesthetic |
| Paliperidone* | Anti-Psychotic |
| Pamidronate Disodium | Anti-Osteoporosis |
| Pantoprazole Sodium Sesquihydrate | Proton pump inhibitor |
| Paroxetine HCl | Anti-Depressant |
| Pemetrexed Disodium* | Anti-Cancer |
| Pentazocine | CNS |
| Pentoxifylline | Anti-Anginal |
| Phentermine HCl | Appetite Suppressant |
| Pioglitazone Hydrochloride | Antidiabetic |
| Pramipexole Di HCl | Anti-Parkinsons |
| Pramlintide Acetate | Anti-Diabetic |
| Prasugrel Hydrochloride* | Anti-Platelet |
| Pregabalin* | Anti-Epileptic |
| Quetiapine Fumarate | Anti-Psychotic |
| Quinapril Hydrochloride | Cardiovascular |
| Rabeprazole sodium | Gastrointestinal |
| Ramipril | Cardiovascular |
| Ranitidine Hydrochloride | Antihistaminic |
| Ranolazine | Anti-Angina |
| Rasagiline Mesylate* | Anti-Parkinsons |
| Repaglinide | Antidiabetic |
| Rifaximin | Anti-bacterial |
| Riluzole | Amyotrophic lateral sclerosis |
| Risedronate Sodium | Anti-Osteoporosis |
| Risperidone | Anti-Psychotic |
| Ritonavir | AntiViral |
| Rivastigmine Base | Anti-Parkinsons |
| Rivastigmine Tartrate | Anti-Parkinsons |
| Rizatriptan Benzoate | Anti-Histamine |
| Rosuvastatin Calcium* | Lipid lowering agent |
| Sertraline Hydrochloride Form I | CNS |
| Sevelamer Carbonate* | Hyperphosphatemia |
| Sevelamer HCl* | Hyperphosphatemia |
| Simvastatin | Cardiovascular |
| Sodium Valproate | Anti-Epileptic |
| Solifenacin Succinate | Antimuscarinic |
| Sumatriptan Succinate | Anti-Migraine |
| Tadalafil | Others |
| Tamsulosin Hydrochloride | Urology |
| Telmisartan | Cardiovascular |
| Temozolomide | Anti-Cancer |
| Tenofovir Disoproxil fumarate | AntiViral |
| Teriparatide | Anti-Osteoporosis |
| Terlipressin Acetate | Vasopressin Agent |
| Testosterone Cypionate | Hormone Replacement Therapy |
| Tiagabine HCl | Anti-Epileptic |
| Tizanidine HCl | Muscle Relaxant |
| Tolterodine tartrate | Antimuscarinic |
| Topiramate | Anti-Epileptic |
| Tramadol HCl | Opioid Analgesic |
| Valacyclovir Hydrochloride | AntiViral |
| Valgancyclovir Hydrochloride (Amorphous Grade) | AntiViral |
| Valgancyclovir Hydrochloride (Crystalline Grade) | AntiViral |
| Valproic Acid | Anti-Epileptic |
| Valsartan | Cardiovascular |
| Venlafaxine Hydrochloride | CNS |
| Voglibose | Antidiabetic |
| Voriconazole | Antifungal |
| Zoledronic Acid | Anti-Osteoporosis |
| Zolmitriptan | Anti-Migraine |
| Zolpidem Tartrate | CNS |
| Zonisamide | Anti-Epileptic |
Product Recalls and Lawsuits
- In March 2015, Ranbaxy Laboratories Ltd was sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market. The suit alleged that Ranbaxy filed “grossly inadequate” applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity.
- In May 2013, Ranbaxy pleaded guilty to federal drug safety violations and paid $500 million in fines to resolve claims that it sold subpar drugs and made false statements to the Food and Drug Administration about its manufacturing practices at two factories in India.
- In 2012, Ranbaxy issued a voluntary retail-level recall for Atorvastatin calcium tablets (Lipitor) because it contained glass particles. Class action lawsuits were filed in New Jersey, United States.
- In 2014, Ranbaxy issued a recall for Atorvastatin calcium after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the U.S. Food and Drug Administration (FDA) said on its website.
- In 2015, Ranbaxy Laboratories Ltd. recalled nearly 30,000 packages of an allergy relief medication – loratadine and pseudoephedrine sulphate packages – that made its way to the United States in February. The U.S. Food and Drug Administration noted that the product was recalled as the result of defective packaging.
- In 2015, Ranbaxy’s parent company Sun Pharma voluntarily recalled 200 vials of its cancer drug, gemcitabine, in the United States. This was because of lack of assurance of sterility of the vials.
Litigation Settlements
- In 2010, Ranbaxy Laboratories Limited and Ranbaxy USA agreed to settle a whistleblower lawsuit and will pay a record $500 million in fines and penalties. This is the largest financial penalty levied against a generic drug company for violations of the Federal Food, Drug and Cosmetic Act. The violations revolve around safety violations that occurred at Ranbaxy USA, a subsidiary of the generic pharmaceutical manufacturer Ranbaxy Laboratories. They generic drug manufacturer is accused of allowing tainted drugs from two manufacturing facilities in India to be distributed within the United States market. As part of the settlement, Ranbaxy agreed to pay to a fine and forfeiture of $150 million, as well as an additional $350 million penalty to settle the civil claims that they submitted false statements to Medicaid, Medicare and other government healthcare programs. Approximately $49 million of the penalty will go to the whistleblower.
- In 2014, Ranbaxy Laboratories paid $39.75 million in tranches to the state of Texas in the U.S. to settle the litigation concerning its participation in the Texas Medicaid Program.
- In 2013, Ranbaxy paid around $420,000 to the U.S. state of Idaho as part of a $500-million settlement that the drug firm had signed with U.S. authorities.
- In 2017, Ranbaxy Laboratories agreed to settle lawsuits accusing it of accepting payments from pharmaceutical company Cephalon Inc to delay the release of a generic version of the latter’s wakefulness drug Provigil.
- In 2008, Ranbaxy settled with pharma giant AstraZeneca in an agreement that will keep Ranbaxy’s generic copies of the blockbuster heartburn drug Nexium off the U.S. market until 2014.
- In 2009, Ranbaxy Laboratories was been slapped with tough penalties by the US Food and Drug Administration (FDA) after it was repeatedly caught falsifying data from one of its four Indian manufacturing plants.
Sources:
https://www.cnbc.com/id/100261384
https://www.abrahamwatkins.com/blog/2012/11/ranbaxy-pharmaceuticals-drug-recall.shtml
https://www.nature.com/news/2009/090302/full/news.2009.130.html
https://www.wsj.com/articles/SB120824391214015579
https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=878399
Tracy Everhart
Tracy Everhart is the Editor for Drug Law Journal. A highly-trained and certified medical professional, Tracy is also an accomplished medical writer. After spending years on the front lines of the medical profession, Tracy now devotes her expertise and skills to researching and reporting on new drugs and devices that enter the market, as well as their side-effects and the real-life stories involved. Prior to joining Drug Law Journal, Tracy wrote for benchmark online healthcare resources focused on families and, in particular, women’s health issues. Tracy holds post-graduate degrees from both the American College of Healthcare Sciences and the Yale School of Nursing. She is also a graduate of both Hampshire College, where she studied microbiology and the University of South Carolina school of nursing.